eFFECTOR Therapeutics, Inc. – NASDAQ:EFTR

Add to watchlist

Market open

Closed in about 2 hours

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	941
Enterprise value	26.87M

P/E	-0.71
EV/Sales	N/A
EV/EBITDA	-1.31
Price/Sales	N/A
Price/Book	3.92
PEG ratio	N/A
EPS	-13.30

Revenue	N/A
EBITDA	-32.85M
Income	-34.63M
Revenue Q/Q	N/A
Revenue Y/Y	-95.44%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR): Profit margin
Jun 2023	0	-8.36M
Sep 2023	0	-8.30M
Dec 2023	162K	-9.12M	-5635.19%
Mar 2024	0	-8.83M

eFFECTOR Therapeutics Financials Estimate

Q Y

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR): Analyst Estimates
2027	51.3M	-38.27M	-74.6%

Analysts Price target
Financials & Ratios estimates

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR): Debt to assets
Jun 2023	26889000	24.31M	90.42%
Sep 2023	20161000	24.12M	119.67%
Dec 2023	20544000	26.33M	128.21%
Mar 2024	27131000	26.30M	96.95%

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR): Cash Flow
Jun 2023	-8.59M	-1.57M	14.57M
Sep 2023	-7.75M	-1.91M	342K
Dec 2023	-5.56M	8.94M	6.10M
Mar 2024	-7.27M	-6.32M	14.23M

eFFECTOR Therapeutics alternative data

eFFECTOR Therapeutics
Employees

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR): Employee count
Aug 2023	15
Sep 2023	15
Oct 2023	15
Nov 2023	15
Dec 2023	15
Jan 2024	15
Feb 2024	15
Mar 2024	15
Apr 2024	14
May 2024	14
Jun 2024	14
Jul 2024	14

eFFECTOR Therapeutics
Hedge Funds Holdings Q1 2023

41.43% -17.65%

of EFTR is owned by hedge funds

16 -14

hedge funds hold EFTR stock

17.05M -7.26M

shares is hold by hedge funds

EFTR hedge funds holdings changes

eFFECTOR Therapeutics
Insider Trading

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR): Insider trades (number of shares)
Period	Buy	Sel
Nov 2023	0	609163

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	27 Nov 2023	SR ONE CAPITAL MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	430,578	$0.61	$261,361
Sale	27 Nov 2023	SR ONE CAPITAL MANAGEMENT, LLC 10 percent owner 10 percent owner	Common Stock	178,585	$0.61	$108,401
Option	11 Aug 2023	WORLAND STEPHEN T director, officer..	Common Stock	33,799	$0.52	$17,575
Option	11 Aug 2023	WORLAND STEPHEN T director, officer..	Stock Option (Right to Buy)	33,799	$0.52	$17,575
Purchase	4 Oct 2022	EHRLICH CHRISTOPHER B director director	Common Stock	346	$0.57	$197
Sale	1 Aug 2022	ROOT JONATHAN D director: director:	Common Stock	1,796	$0.8	$1,444
Sale	28 Jul 2022	ROOT JONATHAN D director: director:	Common Stock	984	$0.89	$878
Sale	25 Jul 2022	ROOT JONATHAN D director: director:	Common Stock	42,344	$0.89	$37,771
Sale	20 Jul 2022	ROOT JONATHAN D director: director:	Common Stock	231	$0.91	$210
Sale	15 Jul 2022	ROOT JONATHAN D director: director:	Common Stock	635	$1.08	$686

EFTR insider trading transactions

eFFECTOR Therapeutics
Executives

Insider	Age	Compensation
Dr. Stephen T. Worland Ph.D. (1958) Chief Executive Officer, Pres & Director	67	$645,250
Dr. Premal Patel M.D., Ph.D. (1970) Chief Medical Officer	55	$541,540
Ms. Alana B. McNulty MBA (1963) Chief Bus. Officer	62	$480,230
Mr. Michael Byrnes M.B.A. (1977) Chief Financial Officer	48	$381,550

eFFECTOR Therapeutics
Latest News

Wednesday, 4 December 2024
07:00	BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board	newsfilecorp.com
Monday, 15 July 2024
09:00	3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off	investorplace.com
Monday, 24 June 2024
07:00	eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	globenewswire.com
Monday, 20 May 2024
08:30	eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	globenewswire.com
Thursday, 9 May 2024
22:56	EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024	InvestorPlace
Tuesday, 9 April 2024
08:00	eFFECTOR Therapeutics to Participate in Upcoming Investor Conference	GlobeNewsWire
Friday, 5 April 2024
14:01	eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails	Zacks Investment Research
Monday, 5 February 2024
08:30	eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	GlobeNewsWire
Tuesday, 30 January 2024
10:56	Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?	Zacks Investment Research
Thursday, 16 November 2023
14:12	3 Top Penny Stocks To Watch Before Next Week	PennyStocks
Tuesday, 24 October 2023
09:02	4 Hot Penny Stocks To Watch With Big News This Week	PennyStocks
Monday, 2 October 2023
15:07	3 Promising Biotech Stocks That Will Make Early Investors Rich	InvestorPlace
Monday, 28 August 2023
11:42	Best Penny Stocks To Buy Now? 10 Under $1 To Watch	PennyStocks
Friday, 25 August 2023
11:06	7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?	PennyStocks
Thursday, 24 August 2023
13:10	Best Penny Stocks To Buy Under $1.25? 3 To Watch Now	PennyStocks
Monday, 10 July 2023
12:16	Best Stocks For Beginners with Little Money: How To Trade Penny Stocks	PennyStocks
Wednesday, 7 June 2023
11:16	Best Penny Stocks To Buy? 5 With Big News This Week	PennyStocks
Monday, 5 June 2023
14:11	Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners	Zacks Investment Research
Wednesday, 31 May 2023
19:47	Stock Market Today: New Penny Stocks Trends & 3 To Watch This Week	PennyStocks
Monday, 29 May 2023
06:00	Evaluating Market Sentiment With Penny Stocks: Top Tools	PennyStocks
Friday, 26 May 2023
08:28	Why Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today?	InvestorPlace
Thursday, 11 May 2023
12:38	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year	InvestorPlace
Tuesday, 28 March 2023
08:30	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences	GlobeNewsWire
Monday, 30 January 2023
08:00	eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference	GlobeNewsWire
Monday, 31 October 2022
14:05	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences	GlobeNewsWire
Wednesday, 21 September 2022
09:00	eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference	GlobeNewsWire
Tuesday, 6 September 2022
08:30	eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference	GlobeNewsWire
Tuesday, 28 June 2022
07:58	4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More	Benzinga
Thursday, 26 May 2022
17:15	eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting	GlobeNewsWire
Wednesday, 9 February 2022
16:00	eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of eFFECTOR Therapeutics stock today?

One share of eFFECTOR Therapeutics stock can currently be purchased for approximately $0.
When is eFFECTOR Therapeutics's next earnings date?

Unfortunately, eFFECTOR Therapeutics's (EFTR) next earnings date is currently unknown.
Does eFFECTOR Therapeutics pay dividends?

No, eFFECTOR Therapeutics does not pay dividends.
How much money does eFFECTOR Therapeutics make?

eFFECTOR Therapeutics has a market capitalization of 941.
What is eFFECTOR Therapeutics's stock symbol?

eFFECTOR Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "EFTR".
What is eFFECTOR Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of eFFECTOR Therapeutics?

Shares of eFFECTOR Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are eFFECTOR Therapeutics's key executives?
eFFECTOR Therapeutics's management team includes the following people:
- Dr. Stephen T. Worland Ph.D. Chief Executive Officer, Pres & Director(age: 67, pay: $645,250)
- Dr. Premal Patel M.D., Ph.D. Chief Medical Officer(age: 55, pay: $541,540)
- Ms. Alana B. McNulty MBA Chief Bus. Officer(age: 62, pay: $480,230)
- Mr. Michael Byrnes M.B.A. Chief Financial Officer(age: 48, pay: $381,550)
How many employees does eFFECTOR Therapeutics have?

As Jul 2024, eFFECTOR Therapeutics employs 14 workers.
When eFFECTOR Therapeutics went public?

eFFECTOR Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 1 Mar 2021.
What is eFFECTOR Therapeutics's official website?

The official website for eFFECTOR Therapeutics is effector.com.
Where are eFFECTOR Therapeutics's headquarters?

eFFECTOR Therapeutics is headquartered at 142 North Cedros Avenue, Solana Beach, CA.
How can i contact eFFECTOR Therapeutics?

eFFECTOR Therapeutics's mailing address is 142 North Cedros Avenue, Solana Beach, CA and company can be reached via phone at 858 925 8215.

eFFECTOR Therapeutics, Inc.

effector.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

858 925 8215

142 North Cedros Avenue
Solana Beach, CA 92075

CIK: 0001828522
ISIN: US28202V2079
CUSIP: 28202V108